✦ LIBER ✦

2.208 Safinamide potentiates the effects of dopamine (DA)-agonists in early stage Parkinson's disease patients

✍ Scribed by R. Borgohain; M. Bhatt; S. Rossetti; R. Anand

Book ID: 117752859
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 58 KB
Volume: 13
Category: Article
ISSN: 1353-8020
DOI: 10.1016/s1353-8020(08)70619-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effect of a D2-specific dopamine ago

The effect of a D2-specific dopamine agonist (Pramipexole) on response time in early Parkinson’s disease patients

✍ Daniel B. Willingham,James P. Bennett,Nevin J. Gkeenberg… 📂 Article 📅 1997 🏛 American Psychological Association 🌐 English ⚖ 795 KB

Impulse control disorders in Chinese Par

Impulse control disorders in Chinese Parkinson’s disease patients: The effect of ergot derived dopamine agonist

✍ M. Auyeung; T.H. Tsoi; W.K. Tang; C.M. Cheung; C.N. Lee; R. Li; Eric Yeung 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 114 KB

2.209 Long-term double-blind, placebo-co

2.209 Long-term double-blind, placebo-controlled evaluation of the safety and efficacy of safinamide as an add-on to stable dopamine agonist therapy in patients with Parkinson's disease

✍ R. Anand; V. Lucini; R. Guiliani; S. Rossetti 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 68 KB

2.229 The effect of pergolide and pramip

2.229 The effect of pergolide and pramipexole on Parkinson tremor in patients with early Parkinson's disease

✍ N. Oztekin; M.F. Oztekin; R. Sarl-Polat; D. Korucu; G. Orhan; F. Ak; M. Saka 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Positron emission tomography demonstrate

Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease

✍ Prof. U. K. Rinne; A. Laihinen; J. O. Rinne; K. Naågren; J. Bergman; U. Ruotsala 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 836 KB

## Abstract Striatal dopamine D~2~ receptor binding was studied in vivo with positron emission tomography in seven patients with early Parkinson's disease using [^11^C]–raclopride. The patients had unilateral symptoms and none of them had received levodopa treatment. The accumulation of [^11^C]–rac

2.205 Design of the A to Z (Agonists to

2.205 Design of the A to Z (Agonists to Zelapar) trial: Adding orally disintegrating selegiline to dopamine agonists in patients with Parkinson's disease experiencing complications

✍ S. Isaacson; R. Pahwa; K.E. Lyons; G. Brunson 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 56 KB